 |
|
|
| |
Dolutegravir is Non-Inferior to Raltegravir and Shows Durable Response Through 96 Weeks: Results From the SPRING-2 Trial
|
| |
| |
Reported by Jules Levin
IAS 2013 Kuala Lumpur June 30-July 3
F Raffi,1 H Jaeger,2 D Motta,3 H Albrecht,4 E Belonosova,5 J Gatell,6 J-G Baril,7 P Domingo,8 C Brennan,9 S Almond,10 S Min9
1Nantes University Hospital, Infectious and Tropical Diseases Department, Nantes, France; 2MUC Research GmbH, Munich, Germany; 3Spedali Civili di Brescia, Brescia, Italy; 4University of South Carolina School of Medicine/Palmetto Health, Columbia, SC, USA; 5Orel Regional Center for AIDS, Orel, Russian Federation; 6Hospital Clinic i Provincial, Barcelona, Spain; 7Clinique Medicale du Quartier Latin, Montreal, Canada; 8Hospital de la Santa Cruz y San Pablo, Barcelona, Spain; 9GlaxoSmithKline, Medicine Discovery and Development, Research Triangle Park, NC, USA; 10GlaxoSmithKline, Clinical Statistics, Mississauga, ON, Canada
|
| |
|
|
|
|
|
